Predictors and implications of estradiol rise after gonadotropin-releasing hormone antagonist initiation during in vitro fertilization cycles

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 54, Issue 4, 2009, Pages 211-217

  Scotchie, Jessica G ^a   Will, Matthew ^a   Fritz, Marc A ^a   Steiner, Anne Z ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cetrorelix; Estradiol; Ganirelix; Gonadotropin releasing hormone antagonist; In vitro fertilization

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRADIOL; ESTROGEN; FOLLITROPIN; GANIRELIX; GESTAGEN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NIDATION; OOCYTE; OOCYTE RETRIEVAL; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; PREGNANCY; PREGNANCY RATE; PROGNOSIS; TREATMENT OUTCOME;

EID: 66949176987     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fluker M, Grifo J, Leader A, et al: Efficacy and safety of ganirelex acetate versus leuprolide acetate in women under-going controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45
2. Del Gadillo JC, Siebzehnrubl E, Dittrich R, et al: Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstim-ulation protocols: A matched study. Eur J Obstet Gynecol Reprod Biol 2002;102:179-183
3. Felberbaum RE, Albano C, Ludwig M, et al: Ovarian stimu-lation for assisted reproduction with hMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: A prospective un-controlled phase III study. Hum Reprod 2000;15:1015-1020
4. The European and Middle East Orgalutran Study Group: Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women under-going ovarian stimulation. Hum Reprod 2001;16:644-651
5. Olivennes F, Belaisch-Allart J, Emperaire JC, et al: Prospec-tive, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Ster-il 2000;73:314-320
6. Borm G, Mannaerts B: Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergo-ing ovarian stimulation with recombinant follicle stimulat-ing hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-1498
7. Albano C, Felberbaum RE, Smitz J, et al: Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000;15:526-531
8. Al-Inany H, Aboulghar M: GnRH antagonist in assisted re-production: A Cochrane review. Hum Reprod 2002;17:874-885
9. Kolibianakis E, Collins J, Tarlatzis B, et al: Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of ana-logue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651-671
10. The Ganirelix Dose-finding Study Group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone (Puregon). Hum Reprod 1998;13:3023-3031
11. Jones H, Acosta A, Andrews M, et al: The importance of the follicular phase to success and failure in in vitro fertilization. Fertil Steril 1983;40:317-321
12. Laufer N, DeCherney A, Tarlatzis B, et al: The association be-tween preovulatory serum 17-beta-estradiol pattern and conception in human menopausal gonadotropin-human chorionic gonadotropin stimulation. Fertil Steril 1986;46:73-76
13. Hassiakos D, Toner J, Muasher S, et al: Implantation and pregnancy rates in relation to oestradiol and progesterone profiles in cycles with and without the use of gonadotrophin-releasing hormone agonist suppression. Hum Reprod 1990; 5:1004-1008
14. Forman R, Robinson J, Egan D, et al: Follicular monitoring and outcome of in vitro fertilization in gonadotropin-releasing hormone-agonist treated cycles. Fertil Steril 1991;55:567-573
15. Fisher S, Grin A, Paltoo A, et al: Falling estradiol levels as a result of intentional reduction in gonadotrophin dose are not associated with poor IVF outcomes, whereas spontaneously falling estradiol levels result in low clinical pregnancy rates. Hum Reprod 2005;20:84-88
16. Styer A, Jackson K, Hornstein M, et al: Pregnancy outcomes in in vitro fertilization cycles with serum estradiol drop prior to human chorionic gonadotropin. Int J Gynaecol Obstet 2005;89:133-137
17. Lindheim SR, Morales AJ: GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048-2051
18. Shapiro D, Mitchell-Leef D, Carter M, et al: Ganirelex acetate use in normal-and poor-prognosis patients and the impact of estradiol patterns. Fertil Steril 2005;83:666-670
19. Lin Y, Seow K, Chen H, et al: Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol. Gynecol Endocrinol 2007;23:45-49